SRR29022835
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.510
- OXIDATIVE_PHOSPHORYLATION+0.480
- MTORC1_SIGNALING+0.420
- INTERFERON_GAMMA_RESPONSE+0.400
- E2F_TARGETS+0.380
- G2M_CHECKPOINT+0.330
- FATTY_ACID_METABOLISM+0.310
- MYC_TARGETS_V2+0.280
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.280
- INTERFERON_ALPHA_RESPONSE+0.270
Top 10 suppressed
- ANGIOGENESIS-0.390
- HEDGEHOG_SIGNALING-0.380
- WNT_BETA_CATENIN_SIGNALING-0.320
- UV_RESPONSE_DN-0.310
- NOTCH_SIGNALING-0.300
- APICAL_SURFACE-0.270
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.260
- ESTROGEN_RESPONSE_EARLY-0.240
- MYOGENESIS-0.230
- TGF_BETA_SIGNALING-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 992ce1bc-46a2-4f57-ac7a-c6368c69c67c | — | — | 0.888 |
| 2 | ERR2208906 | — | — | 0.878 |
| 3 | SRR8518156 | — | D | 0.877 |
| 4 | AUR-AERW-TTM1-A-1-1-R-A742-41 | — | C | 0.870 |
| 5 | TCGA-A2-A0SW-01A-11R-A084-07 | — | C | 0.867 |
| 6 | faffc96a-760c-405c-9bec-d2ec116b4a1d | — | — | 0.847 |
| 7 | 5ffcc7c5-661f-4eed-b5e6-ed158c668321 | — | — | 0.843 |
| 8 | TCGA-C8-A1HM-01A-12R-A137-07 | — | C | 0.840 |
| 9 | C3L-04757 | — | cohortA1 | 0.839 |
| 10 | C3N-03764 | — | cohortA1 | 0.837 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.510 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.480 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.420 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.380 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.330 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.310 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.280 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.280 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.270 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.260 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.260 | Idelalisib | — uncovered |
| COMPLEMENT | 0.240 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.240 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.230 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.210 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.180 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.180 | Temsirolimus | — uncovered |